<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37569549</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>18</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>15</Issue><PubDate><Year>2023</Year><Month>Jul</Month><Day>29</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Nuclear Expression of TDP-43 Is Linked with Morphology and Ubiquitylation of Cytoplasmic Aggregates in Amyotrophic Lateral Sclerosis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">12176</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms241512176</ELocationID><Abstract><AbstractText>The transactive response DNA-binding protein of 43 kDa (TDP-43) is a pathological protein of amyotrophic lateral sclerosis (ALS). TDP-43 pathology is characterized by a combination of the cytoplasmic aggregation and nuclear clearance of this protein. However, the mechanisms underlying TDP-43 pathology have not been fully clarified. The aim of this study was to evaluate the relationships between the expression level of nuclear TDP-43 and the pathological properties of cytoplasmic aggregates in autopsied ALS cases. We included 22 consecutively autopsied cases with sporadic TDP-43-related ALS. The motor neuron systems were neuropathologically assessed. We identified 790 neurons with cytoplasmic TDP-43 inclusions from the lower motor neuron system of included cases. Nuclear TDP-43 disappeared in 84% (<i>n</i> = 660) and expressed in 16% (<i>n</i> = 130) of neurons with cytoplasmic inclusions; the former was defined as TDP-43 cytoplasmic immunoreactivity (c-ir), and the latter was defined as nuclear and cytoplasmic immunoreactivity (n/c-ir). Morphologically, diffuse cytoplasmic inclusions were significantly more prevalent in TDP-43 n/c-ir neurons than in c-ir neurons, while skein-like and round inclusions were less prevalent in n/c-ir neurons. The cytoplasmic inclusions of TDP-43 n/c-ir neurons were phosphorylated but poorly ubiquitylated when compared with those of c-ir neurons. TDP-43 n/c-ir neurons became less dominant than the c-ir neurons among cases with a prolonged disease duration. The expression level of nuclear TDP-43 was significantly lower in n/c-ir neurons than in normal neurons without cytoplasmic inclusions. Our results indicate that the maturation of cytoplasmic TDP-43 inclusions correlates with the depletion of nuclear TDP-43 in each affected neuron. This finding supports the view that an imbalance between nuclear and cytoplasmic TDP-43 may be an essential pathway to TDP-43 pathology.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yabata</LastName><ForeName>Hiroyuki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neuropathology, Institute for Medical Science of Aging, Aichi Medical University, Nagakute 480-1195, Aichi, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Shiga University of Medical Science, Otsu 520-2192, Shiga, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riku</LastName><ForeName>Yuichi</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-6493-8976</Identifier><AffiliationInfo><Affiliation>Department of Neuropathology, Institute for Medical Science of Aging, Aichi Medical University, Nagakute 480-1195, Aichi, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University, Nagoya 466-8550, Aichi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyahara</LastName><ForeName>Hiroaki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neuropathology, Institute for Medical Science of Aging, Aichi Medical University, Nagakute 480-1195, Aichi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akagi</LastName><ForeName>Akio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neuropathology, Institute for Medical Science of Aging, Aichi Medical University, Nagakute 480-1195, Aichi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sone</LastName><ForeName>Jun</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-9057-7609</Identifier><AffiliationInfo><Affiliation>Department of Neuropathology, Institute for Medical Science of Aging, Aichi Medical University, Nagakute 480-1195, Aichi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Urushitani</LastName><ForeName>Makoto</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2773-9836</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Shiga University of Medical Science, Otsu 520-2192, Shiga, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoshida</LastName><ForeName>Mari</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neuropathology, Institute for Medical Science of Aging, Aichi Medical University, Nagakute 480-1195, Aichi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iwasaki</LastName><ForeName>Yasushi</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-0059-3104</Identifier><AffiliationInfo><Affiliation>Department of Neuropathology, Institute for Medical Science of Aging, Aichi Medical University, Nagakute 480-1195, Aichi, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>JP20K16586, JP22K07359, JP23K06935</GrantID><Agency>JSPS KAKENHI</Agency><Country/></Grant><Grant><GrantID>JP20ek0109392, JP20ek0109391</GrantID><Agency>AMED</Agency><Country/></Grant><Grant><GrantID>(30-8)</GrantID><Agency>Intramural Research Grant for Neurological and Psychiatric Disorders of NCNP</Agency><Country/></Grant><Grant><GrantID>not applicable</GrantID><Agency>Grants-in-Aid from the Research Committee of CNS Degenerative Diseases, Research on Policy Planning and Evaluation for Rare and Intractable Diseases, Health, Labour, and Welfare Sciences Research Grants, the Ministry of Health, Labour, and Welfare, Japan</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C531617">Amyotrophic lateral sclerosis 1</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054875" MajorTopicYN="N">Ubiquitination</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">FTLD</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword><Keyword MajorTopicYN="N">and ubiquitin</Keyword><Keyword MajorTopicYN="N">autopsy</Keyword><Keyword MajorTopicYN="N">mislocalization</Keyword><Keyword MajorTopicYN="N">motor neuron</Keyword><Keyword MajorTopicYN="N">spinal cord</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>7</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>12</Day><Hour>10</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>12</Day><Hour>1</Hour><Minute>9</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37569549</ArticleId><ArticleId IdType="pmc">PMC10418808</ArticleId><ArticleId IdType="doi">10.3390/ijms241512176</ArticleId><ArticleId IdType="pii">ijms241512176</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Neumann M., Sampathu D.M., Kwong L.K., Truax A.C., Micsenyi M.C., Chou T.T., Bruce J., Schuck T., Grossman M., Clark C.M., et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T., Hasegawa M., Akiyama H., Ikeda K., Nonaka T., Mori H., Mann D., Tsuchiya K., Yoshida M., Hashizume Y., et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem. Biophys. Res. Commun. 2006;351:602&#x2013;611. doi: 10.1016/j.bbrc.2006.10.093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2006.10.093</ArticleId><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan R.H., Ke Y.D., Ittner L.M., Halliday G.M. ALS/FTLD: Experimental models and reality. Acta Neuropathol. 2017;133:177&#x2013;196. doi: 10.1007/s00401-016-1666-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1666-6</ArticleId><ArticleId IdType="pubmed">28058507</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa M., Arai T., Nonaka T., Kametani F., Yoshida M., Hashizume Y., Beach T.G., Buratti E., Baralle F., Morita M., et al. Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann. Neurol. 2008;64:60&#x2013;70. doi: 10.1002/ana.21425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21425</ArticleId><ArticleId IdType="pmc">PMC2674108</ArticleId><ArticleId IdType="pubmed">18546284</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs K.A., Hodges J.R., Snowden J.S., Mackenzie I.R., Neumann M., Mann D.M., Dickson D.W. Neuropathological background of phenotypical variability in frontotemporal dementia. Acta Neuropathol. 2011;122:137&#x2013;153. doi: 10.1007/s00401-011-0839-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0839-6</ArticleId><ArticleId IdType="pmc">PMC3232515</ArticleId><ArticleId IdType="pubmed">21614463</ArticleId></ArticleIdList></Reference><Reference><Citation>Riku Y., Watanabe H., Yoshida M., Tatsumi S., Mimuro M., Iwasaki Y., Katsuno M., Iguchi Y., Masuda M., Senda J., et al. Lower motor neuron involvement in TAR DNA-binding protein of 43 kDa-related frontotemporal lobar degeneration and amyotrophic lateral sclerosis. JAMA Neurol. 2014;71:172&#x2013;179. doi: 10.1001/jamaneurol.2013.5489.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.5489</ArticleId><ArticleId IdType="pubmed">24378564</ArticleId></ArticleIdList></Reference><Reference><Citation>Geser F., Martinez-Lage M., Robinson J., Uryu K., Neumann M., Brandmeir N.J., Xie S.X., Kwong L.K., Elman L., McCluskey L., et al. Clinical and pathological continuum of multisystem TDP-43 proteinopathies. Arch. Neurol. 2009;66:180&#x2013;189. doi: 10.1001/archneurol.2008.558.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2008.558</ArticleId><ArticleId IdType="pmc">PMC2774117</ArticleId><ArticleId IdType="pubmed">19204154</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E., D&#xf6;rk T., Zuccato E., Pagani F., Romano M., Baralle F.E. Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping. EMBO J. 2001;20:1774&#x2013;1784. doi: 10.1093/emboj/20.7.1774.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/emboj/20.7.1774</ArticleId><ArticleId IdType="pmc">PMC145463</ArticleId><ArticleId IdType="pubmed">11285240</ArticleId></ArticleIdList></Reference><Reference><Citation>Riku Y., Yoshida M., Iwasaki Y., Sobue G., Katsuno M., Ishigaki S. TDP-43 Proteinopathy and Tauopathy: Do They Have Pathomechanistic Links? Int. J. Mol. Sci. 2022;23:15755. doi: 10.3390/ijms232415755.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms232415755</ArticleId><ArticleId IdType="pmc">PMC9779029</ArticleId><ArticleId IdType="pubmed">36555399</ArticleId></ArticleIdList></Reference><Reference><Citation>Wils H., Kleinberger G., Janssens J., Pereson S., Joris G., Cuijt I., Smits V., Ceuterick-de Groote C., Van Broeckhoven C., Kumar-Singh S. TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration. Proc. Natl. Acad. Sci. USA. 2010;107:3858&#x2013;3863. doi: 10.1073/pnas.0912417107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0912417107</ArticleId><ArticleId IdType="pmc">PMC2840518</ArticleId><ArticleId IdType="pubmed">20133711</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J., Del Tredici K., Toledo J.B., Robinson J.L., Irwin D.J., Grossman M., Suh E., Van Deerlin V.M., Wood E.M., Baek Y., et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann. Neurol. 2013;74:20&#x2013;38. doi: 10.1002/ana.23937.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.23937</ArticleId><ArticleId IdType="pmc">PMC3785076</ArticleId><ArticleId IdType="pubmed">23686809</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H., Brettschneider J., Ludolph A.C., Lee V.M., Trojanowski J.Q., Del Tredici K. Amyotrophic lateral sclerosis--a model of corticofugal axonal spread. Nat. Rev. Neurol. 2013;9:708&#x2013;714. doi: 10.1038/nrneurol.2013.221.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2013.221</ArticleId><ArticleId IdType="pmc">PMC3943211</ArticleId><ArticleId IdType="pubmed">24217521</ArticleId></ArticleIdList></Reference><Reference><Citation>Porta S., Xu Y., Restrepo C.R., Kwong L.K., Zhang B., Brown H.J., Lee E.B., Trojanowski J.Q., Lee V.M. Patient-derived frontotemporal lobar degeneration brain extracts induce formation and spreading of TDP-43 pathology in vivo. Nat. Commun. 2018;9:4220. doi: 10.1038/s41467-018-06548-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-06548-9</ArticleId><ArticleId IdType="pmc">PMC6181940</ArticleId><ArticleId IdType="pubmed">30310141</ArticleId></ArticleIdList></Reference><Reference><Citation>Iguchi Y., Eid L., Parent M., Soucy G., Bareil C., Riku Y., Kawai K., Takagi S., Yoshida M., Katsuno M., et al. Exosome secretion is a key pathway for clearance of pathological TDP-43. Brain. 2016;139:3187&#x2013;3201. doi: 10.1093/brain/aww237.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww237</ArticleId><ArticleId IdType="pmc">PMC5840881</ArticleId><ArticleId IdType="pubmed">27679482</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonaka T., Masuda-Suzukake M., Arai T., Hasegawa Y., Akatsu H., Obi T., Yoshida M., Murayama S., Mann D.M., Akiyama H., et al. Prion-like properties of pathological TDP-43 aggregates from diseased brains. Cell Rep. 2013;4:124&#x2013;134. doi: 10.1016/j.celrep.2013.06.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2013.06.007</ArticleId><ArticleId IdType="pubmed">23831027</ArticleId></ArticleIdList></Reference><Reference><Citation>Klim J.R., Williams L.A., Limone F., Guerra San Juan I., Davis-Dusenbery B.N., Mordes D.A., Burberry A., Steinbaugh M.J., Gamage K.K., Kirchner R., et al. ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair. Nat. Neurosci. 2019;22:167&#x2013;179. doi: 10.1038/s41593-018-0300-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0300-4</ArticleId><ArticleId IdType="pmc">PMC7153761</ArticleId><ArticleId IdType="pubmed">30643292</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu L.S., Cheng W.C., Chen C.Y., Wu M.C., Wang Y.C., Tseng Y.H., Chuang T.J., Shen C.J. Transcriptomopathies of pre- and post-symptomatic frontotemporal dementia-like mice with TDP-43 depletion in forebrain neurons. Acta Neuropathol. Commun. 2019;7:50. doi: 10.1186/s40478-019-0674-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-019-0674-x</ArticleId><ArticleId IdType="pmc">PMC6440020</ArticleId><ArticleId IdType="pubmed">30922385</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitra J., Guerrero E.N., Hegde P.M., Liachko N.F., Wang H., Vasquez V., Gao J., Pandey A., Taylor J.P., Kraemer B.C., et al. Motor neuron disease-associated loss of nuclear TDP-43 is linked to DNA double-strand break repair defects. Proc. Natl. Acad. Sci. USA. 2019;116:4696&#x2013;4705. doi: 10.1073/pnas.1818415116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1818415116</ArticleId><ArticleId IdType="pmc">PMC6410842</ArticleId><ArticleId IdType="pubmed">30770445</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C., Wang H., Qiao T., Yang B., Aliaga L., Qiu L., Tan W., Salameh J., McKenna-Yasek D.M., Smith T., et al. Partial loss of TDP-43 function causes phenotypes of amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA. 2014;111:E1121&#x2013;E1129. doi: 10.1073/pnas.1322641111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1322641111</ArticleId><ArticleId IdType="pmc">PMC3970502</ArticleId><ArticleId IdType="pubmed">24616503</ArticleId></ArticleIdList></Reference><Reference><Citation>Igaz L.M., Kwong L.K., Lee E.B., Chen-Plotkin A., Swanson E., Unger T., Malunda J., Xu Y., Winton M.J., Trojanowski J.Q., et al. Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice. J. Clin. Investig. 2011;121:726&#x2013;738. doi: 10.1172/JCI44867.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI44867</ArticleId><ArticleId IdType="pmc">PMC3026736</ArticleId><ArticleId IdType="pubmed">21206091</ArticleId></ArticleIdList></Reference><Reference><Citation>Ke Y.D., van Hummel A., Stevens C.H., Gladbach A., Ippati S., Bi M., Lee W.S., Kr&#xfc;ger S., van der Hoven J., Volkerling A., et al. Short-term suppression of A315T mutant human TDP-43 expression improves functional deficits in a novel inducible transgenic mouse model of FTLD-TDP and ALS. Acta Neuropathol. 2015;130:661&#x2013;678. doi: 10.1007/s00401-015-1486-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1486-0</ArticleId><ArticleId IdType="pubmed">26437864</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamaki Y., Ross J.P., Alipour P., Castonguay C.&#xc9;., Li B., Catoire H., Rochefort D., Urushitani M., Takahashi R., Sonnen J.A., et al. Spinal cord extracts of amyotrophic lateral sclerosis spread TDP-43 pathology in cerebral organoids. PLoS Genet. 2023;19:e1010606. doi: 10.1371/journal.pgen.1010606.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1010606</ArticleId><ArticleId IdType="pmc">PMC9934440</ArticleId><ArticleId IdType="pubmed">36745687</ArticleId></ArticleIdList></Reference><Reference><Citation>Giordana M.T., Piccinini M., Grifoni S., De Marco G., Vercellino M., Magistrello M., Pellerino A., Buccinn&#xe0; B., Lupino E., Rinaudo M.T. TDP-43 redistribution is an early event in sporadic amyotrophic lateral sclerosis. Brain Pathol. 2010;20:351&#x2013;360. doi: 10.1111/j.1750-3639.2009.00284.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1750-3639.2009.00284.x</ArticleId><ArticleId IdType="pmc">PMC8094784</ArticleId><ArticleId IdType="pubmed">19338576</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim G., Bolbolan K., Shahidehpour R., Jamshidi P., Gefen T., Ayala I.A., Weintraub S., Bigio E.H., Mesulam M.M., Geula C. Morphology and Distribution of TDP-43 Pre-inclusions in Primary Progressive Aphasia. J. Neuropathol. Exp. Neurol. 2019;78:229&#x2013;237. doi: 10.1093/jnen/nlz005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/nlz005</ArticleId><ArticleId IdType="pmc">PMC6380320</ArticleId><ArticleId IdType="pubmed">30753613</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatom J.B., Wang D.B., Dayton R.D., Skalli O., Hutton M.L., Dickson D.W., Klein R.L. Mimicking aspects of frontotemporal lobar degeneration and Lou Gehrig&#x2019;s disease in rats via TDP-43 overexpression. Mol. Ther. 2009;17:607&#x2013;613. doi: 10.1038/mt.2009.3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2009.3</ArticleId><ArticleId IdType="pmc">PMC2835101</ArticleId><ArticleId IdType="pubmed">19223871</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T., Hasegawa M., Nonoka T., Kametani F., Yamashita M., Hosokawa M., Niizato K., Tsuchiya K., Kobayashi Z., Ikeda K. Phosphorylated and cleaved TDP-43 in ALS, FTLD and other neurodegenerative disorders and in cellular models of TDP-43 proteinopathy. Neuropathology. 2010;30:170&#x2013;181. doi: 10.1111/j.1440-1789.2009.01089.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1440-1789.2009.01089.x</ArticleId><ArticleId IdType="pubmed">20102522</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandmeir N.J., Geser F., Kwong L.K., Zimmerman E., Qian J., Lee V.M., Trojanowski J.Q. Severe subcortical TDP-43 pathology in sporadic frontotemporal lobar degeneration with motor neuron disease. Acta Neuropathol. 2008;115:123&#x2013;131. doi: 10.1007/s00401-007-0315-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-007-0315-5</ArticleId><ArticleId IdType="pubmed">18004574</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie I.R., Neumann M., Baborie A., Sampathu D.M., Du Plessis D., Jaros E., Perry R.H., Trojanowski J.Q., Mann D.M., Lee V.M. A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol. 2011;122:111&#x2013;113. doi: 10.1007/s00401-011-0845-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0845-8</ArticleId><ArticleId IdType="pmc">PMC3285143</ArticleId><ArticleId IdType="pubmed">21644037</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruijs da Silva L.A., Simonetti F., Hutten S., Riemenschneider H., Sternburg E.L., Pietrek L.M., Gebel J., D&#xf6;tsch V., Edbauer D., Hummer G., et al. Disease-linked TDP-43 hyperphosphorylation suppresses TDP-43 condensation and aggregation. EMBO J. 2022;41:e108443. doi: 10.15252/embj.2021108443.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.2021108443</ArticleId><ArticleId IdType="pmc">PMC9016352</ArticleId><ArticleId IdType="pubmed">35112738</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori F., Tanji K., Zhang H.X., Nishihira Y., Tan C.F., Takahashi H., Wakabayashi K. Maturation process of TDP-43-positive neuronal cytoplasmic inclusions in amyotrophic lateral sclerosis with and without dementia. Acta Neuropathol. 2008;116:193&#x2013;203. doi: 10.1007/s00401-008-0396-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-008-0396-9</ArticleId><ArticleId IdType="pubmed">18560845</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratta S., Tancini B., Sagini K., Delo F., Chiaradia E., Urbanelli L., Emiliani C. Lysosomal Exocytosis, Exosome Release and Secretory Autophagy: The Autophagic- and Endo-Lysosomal Systems Go Extracellular. Int. J. Mol. Sci. 2020;21:2576. doi: 10.3390/ijms21072576.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21072576</ArticleId><ArticleId IdType="pmc">PMC7178086</ArticleId><ArticleId IdType="pubmed">32276321</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou C.C., Zhang Y., Umoh M.E., Vaughan S.W., Lorenzini I., Liu F., Sayegh M., Donlin-Asp P.G., Chen Y.H., Duong D.M., et al. TDP-43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS/FTD. Nat. Neurosci. 2018;21:228&#x2013;239. doi: 10.1038/s41593-017-0047-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-017-0047-3</ArticleId><ArticleId IdType="pmc">PMC5800968</ArticleId><ArticleId IdType="pubmed">29311743</ArticleId></ArticleIdList></Reference><Reference><Citation>White M.A., Kim E., Duffy A., Adalbert R., Phillips B.U., Peters O.M., Stephenson J., Yang S., Massenzio F., Lin Z., et al. TDP-43 gains function due to perturbed autoregulation in a Tardbp knock-in mouse model of ALS-FTD. Nat. Neurosci. 2018;21:552&#x2013;563. doi: 10.1038/s41593-018-0113-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0113-5</ArticleId><ArticleId IdType="pmc">PMC5884423</ArticleId><ArticleId IdType="pubmed">29556029</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin J.A., Wright G.S., Watanabe S., Grossmann J.G., Antonyuk S.V., Yamanaka K., Hasnain S.S. Disease causing mutants of TDP-43 nucleic acid binding domains are resistant to aggregation and have increased stability and half-life. Proc. Natl. Acad. Sci. USA. 2014;111:4309&#x2013;4314. doi: 10.1073/pnas.1317317111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1317317111</ArticleId><ArticleId IdType="pmc">PMC3964094</ArticleId><ArticleId IdType="pubmed">24591609</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Ho W.Y., Lim K., Feng J., Tucker-Kellogg G., Nave K.A., Ling S.C. Cell-autonomous requirement of TDP-43, an ALS/FTD signature protein, for oligodendrocyte survival and myelination. Proc. Natl. Acad. Sci. USA. 2018;115:E10941&#x2013;E10950. doi: 10.1073/pnas.1809821115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1809821115</ArticleId><ArticleId IdType="pmc">PMC6243235</ArticleId><ArticleId IdType="pubmed">30373824</ArticleId></ArticleIdList></Reference><Reference><Citation>Kon T., Mori F., Oyama Y., Tanji K., Kimura T., Takahashi S., Wakabayashi K. An autopsy case of early-stage amyotrophic lateral sclerosis with TDP-43 immunoreactive neuronal, but not glial, inclusions. Neuropathology. 2019;39:224&#x2013;230. doi: 10.1111/neup.12554.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/neup.12554</ArticleId><ArticleId IdType="pubmed">31020724</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H., Ludolph A.C., Neumann M., Ravits J., Del Tredici K. Pathological TDP-43 changes in Betz cells differ from those in bulbar and spinal &#x3b1;-motoneurons in sporadic amyotrophic lateral sclerosis. Acta Neuropathol. 2017;133:79&#x2013;90. doi: 10.1007/s00401-016-1633-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1633-2</ArticleId><ArticleId IdType="pmc">PMC5209403</ArticleId><ArticleId IdType="pubmed">27757524</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks B., Miller R., Swash M., Munsat T. El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Mot. Neuron. Disord. 2000;1:293&#x2013;299. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine T.J., Phelps C.H., Beach T.G., Bigio E.H., Cairns N.J., Dickson D.W., Duyckaerts C., Frosch M.P., Masliah E., Mirra S.S., et al. National Institute on Aging-Alzheimer&#x2019;s Association guidelines for the neuropathologic assessment of Alzheimer&#x2019;s disease: A practical approach. Acta Neuropathol. 2012;123:1&#x2013;11. doi: 10.1007/s00401-011-0910-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0910-3</ArticleId><ArticleId IdType="pmc">PMC3268003</ArticleId><ArticleId IdType="pubmed">22101365</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith I.G., Boeve B.F., Dickson D.W., Halliday G., Taylor J.P., Weintraub D., Aarsland D., Galvin J., Attems J., Ballard C.G., et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017;89:88&#x2013;100. doi: 10.1212/WNL.0000000000004058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004058</ArticleId><ArticleId IdType="pmc">PMC5496518</ArticleId><ArticleId IdType="pubmed">28592453</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingbert C. An enumeration of the medullated nerve fibers in the dorsal roots of the spinal nerves of man. J. Comp. Neurol. 1903;13:53&#x2013;120. doi: 10.1002/cne.910130202.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cne.910130202</ArticleId></ArticleIdList></Reference><Reference><Citation>Riku Y., Iwasaki Y., Ishigaki S., Akagi A., Hasegawa M., Nishioka K., Li Y., Riku M., Ikeuchi T., Fujioka Y., et al. Motor neuron TDP-43 proteinopathy in progressive supranuclear palsy and corticobasal degeneration. Brain. 2022;145:2769&#x2013;2784. doi: 10.1093/brain/awac091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awac091</ArticleId><ArticleId IdType="pubmed">35274674</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>